Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $26.44 Consensus Target Price from Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $26.44.

Several analysts have recently commented on PCRX shares. HC Wainwright increased their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a report on Tuesday, April 8th. Wall Street Zen upgraded Pacira BioSciences from a “hold” rating to a “buy” rating in a report on Friday, June 6th. Barclays increased their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Finally, Needham & Company LLC decreased their price objective on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a report on Friday, May 9th.

Pacira BioSciences Stock Up 0.3%

Pacira BioSciences stock opened at $24.23 on Wednesday. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $29.61. The business has a fifty day moving average of $25.47 and a two-hundred day moving average of $23.83. The company has a quick ratio of 1.99, a current ratio of 2.41 and a debt-to-equity ratio of 0.48. The firm has a market cap of $1.12 billion, a P/E ratio of -10.63 and a beta of 0.52.

Insiders Place Their Bets

In other news, SVP Lauren Riker sold 5,578 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the sale, the senior vice president now owns 59,564 shares of the company’s stock, valued at approximately $1,561,172.44. The trade was a 8.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.40% of the company’s stock.

Institutional Trading of Pacira BioSciences

Institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC raised its position in shares of Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after buying an additional 1,208 shares during the period. Ancora Advisors LLC purchased a new stake in shares of Pacira BioSciences during the 4th quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Pacira BioSciences during the 1st quarter valued at approximately $51,000. Brooklyn Investment Group raised its position in shares of Pacira BioSciences by 372.2% during the 1st quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock valued at $56,000 after buying an additional 1,764 shares during the period. Finally, US Bancorp DE increased its holdings in Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock valued at $56,000 after purchasing an additional 537 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.